Press Releases

Subscribe to our press releases here


Category
Year
Language
31 dec. 2024 08:30:00
Regulatory
Scandinavian Real Heart AB ("Realheart" or the "Company") hereby announces that the subscription price for series TO 2 warrants (the "warrants") has been set at SEK 8.47. The exercise period for the warrants begins on January 2, 2025, and runs until January 31, 2025. The last day for trading the warrants
21 nov. 2024 08:30:00
Västerås, Sweden, November 21, 2024 – Scandinavian Real Heart AB (publ) announces today that the company presented updated safety data from a preclinical study with Realheart® TAH at the 30th Annual Meeting of ISMCS 2024. At the meeting, the company’s R&D engineer Faisal Zaman was nominated
20 nov. 2024 08:30:00
Västerås, Sweden, November 20, 2024 – Scandinavian Real Heart AB (publ) announces today that the company has been granted an approval by Intellectual Property India for its patent application (no. 202117045813) concerning a technical application related to the clinical use of Realheart®
14 nov. 2024 08:00:00
Regulatory
Interim Report
Summary of Interim Report July – September 2024
5 nov. 2024 17:05:00
Regulatory
At the Extraordinary General Meeting in Scandinavian Real Heart AB (“Realheart” or the “Company”) held on 5 November 2024 a reverse share split of 1:100 was resolved upon, whereby one hundred (100) existing shares become one (1) share. Further, the Extraordinary General Meeting resolved
5 nov. 2024 16:55:00
Regulatory
An Extraordinary General Meeting in Scandinavian Real Heart AB (the “Company”) has been held on 5 November 2024 and in particular the following resolutions were made
10 okt. 2024 15:10:00
Västerås, Sweden, October 10, 2024 – Scandinavian Real Heart AB (publ) announces today that the company has entered a collaboration with Professors Arjang Ruhparwar and Jan Schmitto, at the Department of Cardiothoracic, Transplantation and Vascular Surgery at the Hannover Medical School
1 okt. 2024 08:30:00
Västerås, October 1, 2024 – Scandinavian Real Heart AB (publ) announces today that the company has published a preclinical study describing a novel method to simulate hemolysis in artificial heart devices that utilize pumping mechanisms. This unique method will be important in the further development
24 sep. 2024 16:10:00
Regulatory
The shareholders of Scandinavian Real Heart AB, reg. no. 556729–5588 (the "Company"), are hereby invited to an Extraordinary General Meeting on Tuesday, 5 November 2024 at 10.00 at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, SE-722 13 Västerås, Sweden. Registration for the Meeting
5 sep. 2024 12:55:00
Västerås, September 5, 2024 – Scandinavian Real Heart AB (publ) announces today that the company will present new data from two successful preclinical studies evaluating the treatment safety of its total artificial heart Realheart® TAH at the 30th Annual Meeting of the International Society